1333472-09-5

Basic information

• Product Name: 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethan-1-one
• Synonyms: 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethan-1-one
• CAS NO: 1333472-09-5
• Molecular Weight: 498.987
• Mol File: 1333472-09-5.mol

Chemical Properties

• CAS DataBase Reference: 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethan-1-one(1333472-09-5)
• EPA Substance Registry System: 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethan-1-one(1333472-09-5)

Safety Data

• Hazardous Substances Data: 1333472-09-5(Hazardous Substances Data)

Upstream product

• 87199-17-5 4-formylphenylboronic acid, 
• 1333472-89-1 4-(5-methyl-1,3,4-thiadiazole-2-yl)benzaldehyde 
• 427886-20-2 5-bromo-2-chloro-1,3-dimethoxybenzene 
• 1333473-14-5 2-(4-chloro-3,5-dimethoxyphenyl)furan 

Relevant articles and documents

SOLID STATE FORMS OF A PDE10 INHIBITOR

The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical compositions thereof an

PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS

Isolated or pure compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including but not limited to psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Hunti

OPTICALLY ACTIVE PDE10 INHIBITOR

The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-meth

PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF A PDE10 INHIBITOR

The present invention is directed to an improved process for the preparation of compounds of Formula (II) and Formula (III), which are useful in the inhibition of PDE10. In particular, the present invention is directed to an improved process for the prepa

PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.